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Abstract
Cardiovascular disease remains one of the leading causes of death in the United States. 
It is estimated that 1 in every 3 American adults suffer from high blood pressure. 
Hypertension, a precursor to most cardiovascular diseases, continues to grow at an 
alarming rate and is seldom managed carefully. Attempts have been made to manage 
hypertension and reduce the morbidity and mortality of the cardiovascular organ 
through methods including diets, increased amount of exercise, and medications. Many 
commercial drugs have been derived from dihydropyridine due to its antihypertensive 
property. Dihydropyridine derivatives work by acting as calcium channel blockers 
blocking the intake of calcium ions into the vascular smooth muscle and, to a lesser 
extent, cardiac muscles. Dihydropyridine moiety is well-known in pharmacology 
as L-type calcium channel blockers, which is extremely important since it treats 
hypertension in people who suffer from it. It is also highly important to understand 
the antagonists of calcium in the arterial hypertension. A brief overview is presented 
in this mini-review. 
Keywords: Dihydropyridine; Heterocycles; Hypertension; Cardiovascular disease; 
Calcium channel 
Introduction
Several heterocyclic compounds (both synthetic and natural) 
are widely known and many of them possess significant biological 
activities [1-5]. In 2013, four out of top six and nine out of top 
twenty one highest selling drugs were small molecule heterocyclic 
compounds [6]. Dihydropyridine is one of the important 
heterocyclic scaffolds that is frequently found in several medicines 
that include, but are not limited to, L-type calcium channel 
blocker (antihypertensive) [7-9], N-type channel blocker [10,11], 
antianginal [12], antithrombotic [13], antimineralocorticoid [14], 
anticonvulsant [15], anti-inflammatory [16,17], anticancer [18], 
and analgesic [19]. On the other hand, high blood pressure, also 
known as hypertension, is a condition in where a higher than 
normal force pushes against the walls of the arteries as blood is 
pumped through them. It is estimated that 75 million Americans, 
1 in 3 adults, suffers from hypertension. Of that number, only 54% 
have their condition under control. Only in 2014, there were over 
410,000 American deaths in which high blood pressure was the 
primary or contributing factor to the cause of death [20]. This 
mini-review highlights the role of dihydropyridine derivatives 
as potential drugs to manage hypertension and the diseases 
associated with it.
Discussion
In order to a get a clear understanding about the role of 
dihydropyridine derivatives in human body it is important to 
know the role that L-type calcium channels as well as calcium 
channel blockers. A few dihydropyridine derived commercial 
drugs are presented in Figure 1.
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L-type calcium channels
Calcium channels are part of plasma membrane proteins that 
are made up of calcium selective pores that are opened by a change 
in the voltage of the membrane. Calcium channels are found in 
neurons, vascular smooth muscles, cardiac muscles, and other 
excitable cells. Calcium channels are responsible for a variety 
of physiological functions such as neurotransmitter release, 
hormone release, muscle contraction, and vasodilation among 
other things. Calcium channels play a role in a variety of diseases, 
including hypertension [21]. The voltage- dependent calcium ion 
channels of the membrane are subdivided into four fundamental 
types according to their electrophysiology and sensitivity to 
certain drugs and toxins. These channels are called: Channels L, 
which has long activation and high conductance. They are mainly 
located in skeletal, cardiac and vascular muscle and its function 
is contraction. T-channels are transient opening which function 
is calcium ion input to negative levels of membrane potential. 
N-channels which function is to release transmitters in cerebral 
synaptosomes. P-channels which are localized in the cerebellum 
cells. Channels A whose characteristics are still being studied. The 
L-type, N-type and T-type voltage-dependent calcium channels are 
found in the zona glomerulosa in adrenal and the L-type calcium 
channels are a specialized type of voltage-gated calcium channel. 
Voltage-gated calcium channels selectively permeate calcium ions 
into the cell when there is a change from a high voltage to a low 
voltage inside of the cell. L-type calcium channels are the primary 
route for Ca2+ to enter the cardiac muscles [22].
Calcium channel blockers
Calcium channel blockers (also known as calcium channel 
antagonists) are several medications that inhibit the movement 
of Ca2+ through calcium channels. There are three main classes of 
L-type channel blockers: phenylalkyamines, benzothiazapines, 
and 1,4-dihydropyridines. These approved calcium channel 
blockers bind to the L-type calcium channels in the cardiac tissue 
and smooth muscles. Since the function of the calcium channels 
is to regulate the amount of calcium that enters into the cell, 
the function of the calcium channel blockers is to prevent the 
transmembrane protein from allowing calcium into the cell. 
When calcium is allowed into the vascular smooth muscle 
and cardiac muscles it causes smooth muscle contraction. People 
that suffer from high blood pressure do not want their arteries to 
contract because that increases the amount of pressure needed 
to circulate the blood in the body which results in an increased 
amount of strain placed on the heart and other cardiovascular 
organs. 
Having calcium channel blockers inhibit the influx of calcium 
to the cell results in the relaxation of the vascular smooth muscle 
(vasodilation) and decreased systemic vascular resistance which 
lowers blood pressure and arterial pressure, which is a major 
contributor to chest pain (angina) [23].
Mechanism of action
The presence of calcium is essential for muscle to contract and 
according to the different reserve of this ion in the sarcoplasmic 
reticulum of the myofibrils, its absence is noticed with greater 
intensity in the smooth muscle than in the myocardium and 
the striated muscle. For this reason, the action of the calcium 
antagonists is greater on the smooth muscle of the walls. 
Although the entry of calcium ions is required for the release 
of neurotransmitters, calcium antagonists can directly activate 
the release of neurotransmitters through a mechanism that 
does not depend on a reflex response. The release takes place 
by the opening of storage granules. In this regard, the relative 
potency of the calcium antagonists is as follows: felodipine is 
greater than nicardipine and it is greater than amlodipine. The 
potential clinical relevance of these differences in potency should 
never be underestimated because there are many situations 
where the discharge of transmitters is far from desirable, such 
as in myocardial infraction and heart failure. The binding sites 
of calcium with antagonists are heterogeneous. Three sites of 
recognition of the dihydropyridines are known, which are accessed 
from the extracellular surface of the membrane. To some extent, 
the slow onset of the effects of amlodipine and in part its special 
pharmacological profile is a consequence of the ionization of the 
molecule at normal physiological pH, which prevents its approach 
to the binding sites. The participation of calcium ions in smooth 
muscle contraction is a well-known phenomenon. Calcium ion can 
originate from two different sources: The extracellular calcium 
ion, which penetrates fundamentally through the L-type calcium 
ion channels and the calcium ion of the intracellular deposits that 
is released after receiving the corresponding signal. For example 
the neurotransmitter: norepinephrine. 
Regardless of the source, calcium ion, known as calcium 
activator, binds to a regulatory protein, calmodulin that complexes 
with calcium and activates the enzyme protein kinase, which in 
turn facilitates the phosphorylation of myosin. The key event is 
the phosphorylation of myosin, which comes into contact with 
actin and contraction occurs. As the essential characteristic of 
hypertension is the increase in peripheral vascular resistance 
and since smooth muscle contraction depends on calcium ion, its 
antagonists are an effective treatment in this situation provided 
that: A considerable proportion of calcium ion, involved in events 
that culminate with contraction penetrating into the cytosol 
through the channels of calcium ion type L and counteract some 
of the other effects of hypertension, such as cardiac hypertrophy 
and atherosclerosis. 
There are different reasons to argue that excess of calcium 
ion entry through the selective calcium ion L-type channels 
contributes to the increase in vascular resistance induced by 
arterial hypertension. So, intake of calcium ion excess occurs 
because the time is prolonged, resulting in an increase in 
intercellular deposits of exchangeable calcium ion. In the smooth 
muscle cells, the calcium ion tension concentration curve has a 
very steep slope, so that little calcium ion is required to trigger an 
excessive response. Increased arteriolar tone is counteracted by 
the addition of a calcium antagonist. It is admitted that the etiology 
of arterial hypertension is very complex and multifactorial, 
involving different factors such as: genetic predisposition of the 
disease; abnormal operation of the L-type calcium ion channels, 
which implies a relative increase in the number of functional 
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channels as well as the opening time of each channel. Given all 
these elements, it would be very difficult to remove the calcium 
antagonists in the list of drugs potentially useful in hypertension, 
unless their side effects outweigh their beneficial actions. Calcium 
antagonists reduce systolic and diastolic blood pressure without 
causing arthrostatic or postural hypertension, without causing 
water and sodium retention, without altering the circadian 
pattern of blood pressure, without altering the lipid profile in the 
plasma, does not retain uric acid nor alter glycaemia. It maintains 
or improves renal blood flow and the decrease in blood pressure 
they cause does not always lead to a sustained increase in renin 
or angiotensin II. However, in the acute phases, plasma levels of 
noradrenaline may be increased due to a release of the reflex 
stimulated sympathetic neurotransmission in response to the 
sudden drop in peripheral vascular resistance and the direct 
stimulating effect of the release of noradrenaline from the storage 
granules. 
The inherit limitations of these drugs are: its negative inotropic 
effect; in the case of nifedipine the rapidity of the fall in blood 
pressure, which causes reflex achycardia and stimulation of the 
sympathetic and renin-agiotensin systems. Prolonged-release 
preparations attempt to modify these unwanted responses; the 
depressant effect of verapamil, and to a lesser extent, diltiazem on 
the conduction system, determines sustained bradycardia in some 
cases. The reduced plasma half-life necessitates the administration 
of multiple doses, with the exception of amlodipine. 
Therapeutic doses are usually associated with side effects 
such as constipation, bradycardia, edema. Hypertension is a 
vascular disease that is usually accompanied by a decrease, not 
an increase, in cardiac output and volume per heartbeat, so it is 
logical to choose a calcium antagonist with vascular selectivity 
that does not stimulate the release of catecholamine. The 
problem would be to know if they are still effective. At present, 
antagonists with vascular selectivity share two characteristics: 
they all are dihydropyridine derived, and as a consequence of 
their selectivity, are a logical alternative in the treatment of 
arterial hypertension. However, there are differences between 
the different selective vascular drugs, so amlodipine does not 
modify plasma noradrenalide, felodipine causes an increase that 
persists often in prolonged treatment. In the case of amlodipine, 
its hypotensive effect occurs without increasing the heart 
rate, whereas felodipine usually produces a reflex tachycardia. 
Amlodipine as a consequence of its prolonged plasma half-life and 
high bioavailability can be administered in a single dose per day; 
On the other hand, its action starts slowly and the possibility of 
producing reflex changes in the heart rate is quite remote, does 
not produce changes in plasma volume or sodium ion retention, 
nor does it present significant alterations in the logogram.
Antagonists with vascular selectivity reduce systemic pressure 
by decreasing peripheral vascular resistance and not by changes 
in cardiac output or volume depletion. Nifedipine may possibly 
meet the requirements of being a selective antagonist by exerting 
its best effect on the vessels compared to the myocardium, and 
also has no (or very little) effect on nodal tissue or atrioventricular 
conduction; The problem is that its selectivity for vessels is 
associated with rapid uptake and plasma distribution, as well 
as a rapid rate of fixation to its “receptor” in the complex of the 
calcium ion channel, for this reason produces rapid peripheral 
vasodilation. As a consequence, the autonomic nervous system 
is stimulated, determining a rapid and significant increase of the 
heart rate, which forces to concomitant treatment with β-blocker 
or a preparation of prolonged release [24-29].
Conclusion
Clinical and laboratory observations of prototypes of calcium 
antagonists have revealed some interesting and possibly 
unexpected but clinically useful properties of these drugs. 
Thus, they are known to interfere with the processes leading to 
atherogenic development, to delay left ventricular hypertrophy 
induced by hypertension, to inhibit the growth of cancer cells, to 
improve the viability of the conserved organs, to protect against 
the destructive effect of free radicals and act as antiepileptics 
or potentiate the antimalarial effects of chloroquine. These 
properties, or at least some of them, should be maintained in the 
new generation of dihydropyrine-containing calcium antagonists. 
Amlodipine, nitrendipine, felodipine, nisoldipine prolong their 
half-life in patients with liver dysfunction. The antagonists 
are metabolized in the liver and therefore the dosage must be 
carefully adjusted in these cases.
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